US20220153699A1 - Synthesis of 4-amino-5-methyl-1h-pyridin-2(1h)-on (intermediate compound for the synthesis of the mr antagonist finerenone) from 2-chloro-5-methyl-4-nitro-pyridine-1-oxide using the intermediate compound 2-chloro-5-methyl-4-pyridinamine - Google Patents

Synthesis of 4-amino-5-methyl-1h-pyridin-2(1h)-on (intermediate compound for the synthesis of the mr antagonist finerenone) from 2-chloro-5-methyl-4-nitro-pyridine-1-oxide using the intermediate compound 2-chloro-5-methyl-4-pyridinamine Download PDF

Info

Publication number
US20220153699A1
US20220153699A1 US17/435,606 US202017435606A US2022153699A1 US 20220153699 A1 US20220153699 A1 US 20220153699A1 US 202017435606 A US202017435606 A US 202017435606A US 2022153699 A1 US2022153699 A1 US 2022153699A1
Authority
US
United States
Prior art keywords
methyl
chloro
synthesis
formula
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/435,606
Inventor
Johannes Platzek
Kai Lovis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Bayer Pharma AG
Original Assignee
Bayer AG
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG, Bayer Pharma AG filed Critical Bayer AG
Assigned to BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFT reassignment BAYER AKTIENGESELLSCHAFT ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LOVIS, KAI, PLATZEK, JOHANNES
Publication of US20220153699A1 publication Critical patent/US20220153699A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Definitions

  • the present invention relates to a novel and improved method for preparing 4-amino-5-methylpyridone of the formula (I)
  • 4-Amino-5-methylpyridone of the formula (I) is prepared by reacting chloro-methyl-aminopyridine (2) with KOH in methanol in an autoclave at elevated temperature.
  • the invention also relates to a method for preparing chloro-methyl-aminopyridine (2)
  • the compound of the formula (I) is a key intermediate for the preparation of finerenone (II):
  • Finerenone (II) acts as a nonsteroidal antagonist of the mineralocorticoid receptor and can be used as an agent for the prophylaxis and/or treatment of cardiovascular and renal disorders such as heart failure and diabetic nephropathy.
  • a disadvantage of the method is the use of a very large excess of benzylamine: for 30 mmol of the compound of the formula (III), 30 ml (275.2 mmol) is used, which is a 9.17-fold excess based on compound (III).
  • the recycling of excess benzylamine is laborious and associated with considerable costs.
  • the reaction is carried out in boiling benzylamine (185° C.), the reaction time is 36 hours. Such high temperatures are not practicable in standard stirred apparatuses and require special technical equipment.
  • by-product (VI) was in particular observed, which is attributable to traces of palladium from the precursor for (III):
  • the catalyst is filtered off and the filtrate evaporated to dryness, traces of acetic acid are removed by azeotroping with toluene and the residue is taken up in acetone or methyl ethyl ketone and filtered.
  • This process is technically not feasible when upscaling, since stirred apparatuses do not evaporate to dryness.
  • three different solvents are needed for the isolation.
  • the strongly coloured reaction product is then further purified by chromatography (dichloromethane/MeOH 1:1), which is something else that would if possible need to be avoided in an industrial-scale process.
  • the overall yield over 4 chemical steps, starting from malonyl chloride, is 21.4% of theory.
  • the problem addressed by the present invention was that of developing an alternative synthesis for the process intermediate 4-amino-5-methylpyridone as an intermediate for the preparation of the compound of the formula (II), finerenone, in particular a method that is readily executable on an industrial scale, is cost-effective and avoids large excesses of solvent, and uses reagents that are more environmentally friendly.
  • the target compound (I) is obtained by reacting compound (2) in an autoclave at elevated temperature under either acidic or basic conditions. A similar reaction with NaOH in methanol is described in Tetrahedron 55 (1999), p. 11 985. The product is purified by chromatography. Unfortunately the reaction of compound 2 under these conditions afforded a mixture of target compound (I) and the 2-methyl ether (7):
  • This mixture could be separated only by chromatography.
  • the conversion into the target compound proceeds very smoothly when potassium hydroxide (KOH) is used instead of sodium hydroxide.
  • KOH potassium hydroxide
  • the reaction also proceeds in methanol as solvent without the methyl ether (7) being obtained as a by-product.
  • the reaction is carried out in an autoclave at temperatures of 160 to 200° C., preferably at 180° C. Reaction times are 15-48 hours, depending on the chosen temperature, i.e. inter alia the reaction times tend to be shorter at higher temperatures.
  • the reaction mixture is neutralized (to approx.
  • the present invention accordingly provides a method for preparing the process intermediate 4-amino-5-methylpyridone of the formula (I), characterized in that chloro-methyl-aminopyridine (2) is reacted with KOH in methanol in an autoclave.
  • the method is executed at temperatures of 160° C. to 200° C., in particular at 180° C.
  • a further aspect of the invention is a novel method for preparing chloro-methyl-aminopyridine (2):
  • reaction is absent in this novel inventive method or observed only to a very minor degree ( ⁇ 1%), which would therefore be surprising and unexpected to those skilled in the art.
  • the reaction is preferably carried out in protic solvents, for example alcohols such as ethanol, methanol, isopropanol, n-propanol and n-butanol. It is however also possible to use solvents such as THF, dioxane and 2-methyl-THF. In some cases, the addition of water can be advantageous.
  • the catalyst used is preferably a platinum-containing catalyst.
  • the following platinum catalysts may be used:
  • the hydrogen pressure during the hydrogenation should be between 2 and 7 bar, preferably 2 and 5 bar, more preferably 3 bar.
  • the temperature should be between 20 and 50° C., but preferably between 25 and 30° C., more preferably 30° C.
  • the reaction time is 10 to 30 hours, preferably 18 to 22 h.
  • the catalyst is filtered off and the solution concentrated to small volume and redistilled onto the solvent of the following reaction, preferably methanol. It is advantageous when the crude product is used directly in the following reaction. The reaction proceeds quantitatively.
  • the present invention further provides a method for preparing the process intermediate chloro-methyl-aminopyridine (2) by hydrogenating nitro-N-oxide (3) on a platinum catalyst.
  • platinum (Pt)+0.6% molybdenum (Mo) on carbon powder is used as catalyst.
  • 1% platinum (Pt)+2% vanadium (V) on carbon powder is used as catalyst.
  • platinum (Pt)+0.3% molybdenum (Mo) on carbon powder is used as catalyst.
  • a further advantage of the method is that compound (2) can be converted into compound (I) directly, without further purification.
  • the present invention further provides a method for preparing the process intermediate 4-amino-5-methylpyridone of the formula (I), characterized in that the intermediate nitro-N-oxide (3) is first hydrogenated on a platinum catalyst and the resulting intermediate chloro-methyl-aminopyridine (2) then reacted with potassium hydroxide (KOH) in methanol in an autoclave.
  • KOH potassium hydroxide
  • a glass pressure reactor with cross-beam stirrer was charged under argon with 29 g (153.788 mmol) of 2-chloro-5-methyl-4-nitro-1-oxidopyridin-1-ium (compound 3, Heterocycles, vol. 78, No. 11, 2009, p. 2811) and 2.9 g of hydrogenation catalyst (0.8% Pt and 0.6% Mo on activated carbon (D505A-105 0.8% Pt+0.6% Mo on carbon powder, BASF) and 320 ml of ethanol were added.
  • the reactor was closed and inertized three times, each time with 3 bar argon overpressure. Hydrogenation was then carried out for 20 hours at 30° C. under a 3 bar hydrogen overpressure (conversion >98%).
  • the reactor was inertized with argon and the reaction solution filtered through 10 g of kieselguhr. The filtrate was concentrated to dryness under reduced pressure.
  • a pressure reactor was charged with 4.0 g of the title compound from Example 1 (compound 2) in 40 ml of methanol and 12.5 g of potassium hydroxide (KOH) was added. This was then heated to 180° C. for 16 hours (rise in pressure to 12.5 bar). It was allowed to cool.
  • KOH potassium hydroxide
  • the method of the invention represents a very efficient, shorter synthesis without the use of chromatography, that is also suitable for upscaling.
  • the method of the invention it was possible, starting from the nitro-N-oxide (3), to prepare via two chemical steps the target compound (I) in an overall yield of 84% in high purity (>99%).

Abstract

The present invention relates to a novel and improved method for preparing 4-amino-5-methylpyridone of the formula (I)
Figure US20220153699A1-20220519-C00001
which is an intermediate in the preparation of the MR antagonist finerenone.

Description

  • The present invention relates to a novel and improved method for preparing 4-amino-5-methylpyridone of the formula (I)
  • Figure US20220153699A1-20220519-C00002
  • 4-Amino-5-methylpyridone of the formula (I) is prepared by reacting chloro-methyl-aminopyridine (2) with KOH in methanol in an autoclave at elevated temperature.
  • Figure US20220153699A1-20220519-C00003
  • The invention also relates to a method for preparing chloro-methyl-aminopyridine (2)
  • Figure US20220153699A1-20220519-C00004
  • In the method, the nitro-N-oxide of the formula (3)
  • Figure US20220153699A1-20220519-C00005
  • is hydrogenated on a platinum catalyst, yielding chloro-methyl-aminopyridine (2). With the method of the invention it is possible, starting from the nitro-N-oxide (3), to prepare via two chemical steps the target compound (I) in an overall yield of 84% in high purity (>99%).
  • Figure US20220153699A1-20220519-C00006
  • The compound of the formula (I) is a key intermediate for the preparation of finerenone (II):
  • Figure US20220153699A1-20220519-C00007
  • Finerenone (II) acts as a nonsteroidal antagonist of the mineralocorticoid receptor and can be used as an agent for the prophylaxis and/or treatment of cardiovascular and renal disorders such as heart failure and diabetic nephropathy.
  • The compound of the formula (II) and the process for the preparation thereof are described in WO 2008/104306 and ChemMedChem 2012, 7, 1385 and also in WO 2016/016287 A1 (Bayer Pharma AG), both publications disclosing a detailed discussion of the research synthesis. A disadvantage of the synthesis described therein is the fact that this synthesis is unsuitable for a further industrial-scale process, since many steps proceed at very high dilution, with very high excesses of reagents, and therefore in a relatively low yield overall.
  • There was accordingly a need for a synthesis that can be executed on an industrial scale and that reproducibly affords the process intermediate of the formula (I) in high overall yield, with low production costs and in high purity, and that meets all regulatory requirements, in order to supply clinical trials with active substance and for use in subsequent regulatory submissions.
  • The preparation of compound (I) is described in Synthesis, p. 765 (1984) (Example 3c). Starting from malonyl chloride and propionitrile, the chloropyridine hydrochloride is obtained in a yield of 40% of theory, which is then directly hydrogenated with Pd/C: 86% of theory. The overall yield over the two steps is 34.4% of theory.
  • Figure US20220153699A1-20220519-C00008
  • Starting from hydroxypyridone (III), which is described in Example 1c of the publication in Synthesis, reaction in boiling benzylamine (IV) affords compound (V). The benzyl group in compound (V) is then hydrolytically cleaved by catalytic hydrogenation over palladium/carbon. The overall yield over the two steps is 62.4% of theory.
  • Figure US20220153699A1-20220519-C00009
  • A disadvantage of the method is the use of a very large excess of benzylamine: for 30 mmol of the compound of the formula (III), 30 ml (275.2 mmol) is used, which is a 9.17-fold excess based on compound (III). The recycling of excess benzylamine is laborious and associated with considerable costs. The reaction is carried out in boiling benzylamine (185° C.), the reaction time is 36 hours. Such high temperatures are not practicable in standard stirred apparatuses and require special technical equipment. On repeating the procedure, by-product (VI) was in particular observed, which is attributable to traces of palladium from the precursor for (III):
  • Figure US20220153699A1-20220519-C00010
  • Under the harsh reaction conditions, dehydrogenation to benzylimine occurs, which then decomposes to benzaldehyde (water is formed during the reaction), the benzaldehyde condensing with the compound of the formula (III) to form the compound of the formula (VI). This by-product forms particularly on scale-up of the batches (up to >10%) and is carried over as far as the compound of the formula (I). The reaction solution is worked up by cooling to room temperature, washing the precipitated crystals with methyl ethyl ketone and o-dichlorobenzene and then recrystallizing from o-dichlorobenzene. Here too, it would be advantageous to dispense with chlorinated solvents and pursue more environmentally friendly variants.
  • The subsequent debenzylation takes place in glacial acetic acid, 10 mmol in 200 ml, which is 2.14 g of compound (V) in 200 ml. This corresponds to a 93.45-fold excess, which means that, for 1 kg of (V), 93.45 L of acetic acid would be required. These are huge excesses that are out of the question for an industrial process. Moreover, for the conversion of 10 mmol of (V), 600 mg of Pd catalyst on carbon (10% and 30%) is used. This means that, in order to debenzylate 1 kg of compound (V), 280 g of catalyst would be necessary. This too is impractical from an industrial and economic viewpoint. For workup, the catalyst is filtered off and the filtrate evaporated to dryness, traces of acetic acid are removed by azeotroping with toluene and the residue is taken up in acetone or methyl ethyl ketone and filtered. This process is technically not feasible when upscaling, since stirred apparatuses do not evaporate to dryness. Furthermore, three different solvents are needed for the isolation. The strongly coloured reaction product is then further purified by chromatography (dichloromethane/MeOH 1:1), which is something else that would if possible need to be avoided in an industrial-scale process. The overall yield over 4 chemical steps, starting from malonyl chloride, is 21.4% of theory.
  • The problem addressed by the present invention was that of developing an alternative synthesis for the process intermediate 4-amino-5-methylpyridone as an intermediate for the preparation of the compound of the formula (II), finerenone, in particular a method that is readily executable on an industrial scale, is cost-effective and avoids large excesses of solvent, and uses reagents that are more environmentally friendly.
  • With the present invention, a very efficient synthesis has been found that allows the disadvantages mentioned above to be circumvented. Starting from the chloro-methyl-aminopyridine (2) known in the literature
  • Figure US20220153699A1-20220519-C00011
  • the target compound (I) is obtained by reacting compound (2) in an autoclave at elevated temperature under either acidic or basic conditions. A similar reaction with NaOH in methanol is described in Tetrahedron 55 (1999), p. 11 985. The product is purified by chromatography. Unfortunately the reaction of compound 2 under these conditions afforded a mixture of target compound (I) and the 2-methyl ether (7):
  • Figure US20220153699A1-20220519-C00012
  • This mixture could be separated only by chromatography.
  • Surprisingly, the conversion into the target compound proceeds very smoothly when potassium hydroxide (KOH) is used instead of sodium hydroxide. Then the reaction also proceeds in methanol as solvent without the methyl ether (7) being obtained as a by-product. Preference is given to using pure methanol as solvent, but it is also possible to use aqueous methanol. The reaction is carried out in an autoclave at temperatures of 160 to 200° C., preferably at 180° C. Reaction times are 15-48 hours, depending on the chosen temperature, i.e. inter alia the reaction times tend to be shorter at higher temperatures. For workup, the reaction mixture is neutralized (to approx. pH 7) with a mineral acid, for example hydrochloric acid, sulfuric acid or phosphoric acid, preferably hydrochloric acid, and then concentrated to small volume and water removed azeotropically by adding to ethanol. Finally, it is redistilled in methanol and the salts are filtered off. It is concentrated to small volume and redistilled on water. For recrystallization, it is concentrated to about three times the amount by volume (based on starting material 2). After cooling to 0° C., the product is isolated, for example by filtration, washed if necessary with a little cold water and dried under reduced pressure at elevated temperature (30-70° C.).
  • The present invention accordingly provides a method for preparing the process intermediate 4-amino-5-methylpyridone of the formula (I), characterized in that chloro-methyl-aminopyridine (2) is reacted with KOH in methanol in an autoclave.
  • In a preferred embodiment, the method is executed at temperatures of 160° C. to 200° C., in particular at 180° C.
  • A further aspect of the invention is a novel method for preparing chloro-methyl-aminopyridine (2):
  • Figure US20220153699A1-20220519-C00013
  • In this method, the use of a Pt catalyst reduces the nitro group and the nitro-N-oxide at the same time. A catalytic hydrogenation reaction of this kind, in a pyridine having a substitution pattern of this kind, is as yet undescribed in the literature.
  • The preparation of compound 2 is known from the literature (WO 2005/100342 A1), the desmethyl compound of 2 is likewise known and is prepared by similar methods (Tetrahedron 55 (1999), p. 1195), but the industrial-scale transfer (upscaling) of the methods described therein is difficult, since they include working with elemental zinc or iron under acidic conditions, preferably acetic acid. The use of Raney nickel as hydrogenation catalyst is likewise possible, but upscaling is problematic, since Raney nickel wastes are extremely pyrophoric. Moreover, the industrial execution is also a safety challenge, since the strong exothermicity means that the reaction is not easy to control. Furthermore, workup becomes very difficult and laborious and on top of that generates a lot of metal salt waste that must be disposed of, which is not inconsequential when producing such products on the ton scale.
  • A commonly occurring side reaction in the reduction of 2-chloro-substituted pyridine derivatives is the concomitant reduction of the chlorine atom to hydrogen (compound 4).
  • Figure US20220153699A1-20220519-C00014
  • This side reaction is absent in this novel inventive method or observed only to a very minor degree (<<1%), which would therefore be surprising and unexpected to those skilled in the art. The reaction is preferably carried out in protic solvents, for example alcohols such as ethanol, methanol, isopropanol, n-propanol and n-butanol. It is however also possible to use solvents such as THF, dioxane and 2-methyl-THF. In some cases, the addition of water can be advantageous.
  • The catalyst used is preferably a platinum-containing catalyst. The following platinum catalysts may be used:
  • 0.8% Pt + 0.6% Mo on carbon powder
    1% Pt + 2% V on carbon powder
    0.5% Pt + 0.3% Mo on carbon powder
  • Particular preference is given to using 0.8% Pt +0.6% Mo on carbon powder (from BASF). The hydrogen pressure during the hydrogenation should be between 2 and 7 bar, preferably 2 and 5 bar, more preferably 3 bar. The temperature should be between 20 and 50° C., but preferably between 25 and 30° C., more preferably 30° C. The reaction time is 10 to 30 hours, preferably 18 to 22 h.
  • For isolation, the catalyst is filtered off and the solution concentrated to small volume and redistilled onto the solvent of the following reaction, preferably methanol. It is advantageous when the crude product is used directly in the following reaction. The reaction proceeds quantitatively.
  • The preparation of the nitro-N-oxide (3) is known from the literature, as described for example in Heterocycles, vol. 78, No. 11, 2009, p. 2811 or in WO 2005/100342 A1.
  • In Heterocycles, vol. 78, No. 11, 2009 the following yields for the preparation of compound 3 are described: overall yield of theory over 2 steps 64%.
  • Figure US20220153699A1-20220519-C00015
  • The present invention further provides a method for preparing the process intermediate chloro-methyl-aminopyridine (2) by hydrogenating nitro-N-oxide (3) on a platinum catalyst.
  • In a preferred embodiment, 0.8% platinum (Pt)+0.6% molybdenum (Mo) on carbon powder is used as catalyst.
  • In a further preferred embodiment, 1% platinum (Pt)+2% vanadium (V) on carbon powder is used as catalyst.
  • In a further preferred embodiment, 0.5% platinum (Pt)+0.3% molybdenum (Mo) on carbon powder is used as catalyst.
  • With the novel inventive method it is possible, starting from the nitro-N-oxide (3), to prepare via two chemical steps
  • Figure US20220153699A1-20220519-C00016
  • the target compound (I) in an overall yield of 84% in high purity (>99%). A further advantage of the method is that compound (2) can be converted into compound (I) directly, without further purification.
  • If the yields of the novel method are combined with those known from the literature, starting from the inexpensive and commercially very readily obtainable 2-chloromethylpyridine (5), an overall yield of 54% of theory is achieved, which is an approximately 2.5-fold improvement in yield compared with the prior art method described in Synthesis.
  • The present invention further provides a method for preparing the process intermediate 4-amino-5-methylpyridone of the formula (I), characterized in that the intermediate nitro-N-oxide (3) is first hydrogenated on a platinum catalyst and the resulting intermediate chloro-methyl-aminopyridine (2) then reacted with potassium hydroxide (KOH) in methanol in an autoclave.
  • The paragraphs that follow relate to embodiments of the invention:
  • 1. Method for preparing the process intermediate 4-amino-5-methylpyridone of the formula (I)
  • Figure US20220153699A1-20220519-C00017
      • characterized in that chloro-methyl-aminopyridine (2)
  • Figure US20220153699A1-20220519-C00018
      • is reacted with KOH in methanol in an autoclave.
  • 2. Method according to paragraph 1, characterized in that it is executed at temperatures of 160° C. to 200° C.
  • 3. Method for preparing the process intermediate chloro-methyl-aminopyridine (2),
  • Figure US20220153699A1-20220519-C00019
      • characterized in that nitro-N-oxide (3)
  • Figure US20220153699A1-20220519-C00020
      • is hydrogenated on a platinum catalyst.
  • 4. Method according to paragraph 3, characterized in that 0.8% platinum+0.6% molybdenum on carbon powder is used as catalyst.
  • 5. Method according to paragraph 3, characterized in that 1% platinum+2% vanadium on carbon powder is used as catalyst.
  • 6. Method according to paragraph 3, characterized in that 0.5% platinum+0.3% molybdenum on carbon powder is used as catalyst.
  • 7. Method for preparing the process intermediate 4-amino-5-methylpyridone of the formula (I), characterized in that the nitro-N-oxide (3) intermediate is first hydrogenated on a platinum catalyst and the resulting chloro-methyl-aminopyridine (2) intermediate is then reacted with KOH in methanol in an autoclave.
  • EXAMPLES Example 1 Preparation of 2-chloro-5-methylpyridin-4-amine (Compound 2)
  • A glass pressure reactor with cross-beam stirrer was charged under argon with 29 g (153.788 mmol) of 2-chloro-5-methyl-4-nitro-1-oxidopyridin-1-ium (compound 3, Heterocycles, vol. 78, No. 11, 2009, p. 2811) and 2.9 g of hydrogenation catalyst (0.8% Pt and 0.6% Mo on activated carbon (D505A-105 0.8% Pt+0.6% Mo on carbon powder, BASF) and 320 ml of ethanol were added. The reactor was closed and inertized three times, each time with 3 bar argon overpressure. Hydrogenation was then carried out for 20 hours at 30° C. under a 3 bar hydrogen overpressure (conversion >98%). The reactor was inertized with argon and the reaction solution filtered through 10 g of kieselguhr. The filtrate was concentrated to dryness under reduced pressure.
  • Yield: 23.0 g (quantitative, product still contained ethanol), purity: 97.5% (HPLC)
  • MS (EIpos): m/z=143 [M+H]+
  • 1H-NMR (300 MHz, DMSO-d6): δ=1.96 (s, 3H), 6.16 (br s, 2H), 6.50 (s, 1H), 7.68 (s, 1H)
  • In an analogous manner, a conversion of approx. 98% was achieved with a catalyst consisting of 0.8% Pt and 0.3% Mo on activated carbon. Use of 1% Pt+2% V on activated carbon achieved a conversion of approx. 87%.
  • Example 2 Preparation of 4-amino-5-methyl-1H-pyridin-2-One (I)
  • A pressure reactor was charged with 4.0 g of the title compound from Example 1 (compound 2) in 40 ml of methanol and 12.5 g of potassium hydroxide (KOH) was added. This was then heated to 180° C. for 16 hours (rise in pressure to 12.5 bar). It was allowed to cool.
  • The reaction was carried out 5 times with in each case 4.0 g of the title compound from Example 1 and the reaction solutions combined after cooling.
  • Workup: The mixture was adjusted to pH 7.0 with approx. 100 ml of aq. 25% hydrochloric acid while cooling, then evaporated to dryness under reduced pressure, and the residue azeotroped 5 times with ethanol, each time with 50 ml (evaporated to dryness under reduced pressure to remove traces of water). 400 ml of methanol was added to the evaporation residue and the mixture was stirred. The salt (KCl) was filtered off and washed with two 25 ml portions of methanol. The filtrate was concentrated to dryness under reduced pressure. The evaporation residue was recrystallized from 60 ml of water. After cooling to 0° C., the precipitated crystals were filtered off. The wet product was then dried under reduced pressure at 30° C.
  • Yield: 13.5 g (77.53% of theory); purity according to HPLC: 99.1%
  • A further 1.10 g (6.32% of theory) was isolated from the mother liquor, thereby achieving an overall yield of approx. 84% of theory.
  • MS (EIpos): m/z=125 [M+H]+
  • 1H-NMR (300 MHz, DMSO-d6): δ=1.81 (s, 3H), 2.54 (s, 1H), 5.24 (s, 1H), 5.79 (s, 2H), 6.85 (s, 1H), 10.27 (br s, 1H)
  • From what has been described above, it is clear that the methods available up to now have the disadvantages that
      • (1) a multistep synthesis is carried out,
      • (2) the by-products of the formula (VI) (up to >10%), of the formula (4) and/or of the formula (7) are formed, which occur as impurities in the preparation of the compound of the formula (I) and need to be removed by laborious chromatographic processes,
      • (3) benzylamine is used in a very large excess, the recycling of which is laborious and associated with considerable costs,
      • (4) the reaction needs to be carried out in boiling benzylamine at 185° C. and with a reaction time of 36 hours, since such high temperatures are not practicable in standard stirred apparatuses and require special technical equipment,
      • (5) chlorinated solvents are used, which are not environmentally friendly, and
      • (6) large amounts of Pd catalyst on carbon need to be used, the separation and processing of which is not only laborious, but also scarcely practicable in an industrial-scale synthesis.
  • By contrast, the method of the invention avoids these disadvantages and achieves the following effects and advantages:
      • (1) the method/synthesis needs fewer steps in order to afford the compound of the formula (I) or the compound of the formula (2),
      • (2) the compound of the formula (I) is obtained in high purity directly, without purification,
      • (3) the compounds of the formulas (VI), (4) and/or (7) do not form as undesired by-products,
      • (4) chromatographic separation, as is described in the prior art, is not required, thus making this novel inventive method very attractive as regards upscaling for production on a large scale,
      • (5) the repeated use of solvents, in particular chlorinated solvents, can be eliminated in part or altogether, making the method of the invention much more environmentally friendly and
      • (6) much lower reaction times and/or lower reaction temperatures are required.
  • Overall, the method of the invention represents a very efficient, shorter synthesis without the use of chromatography, that is also suitable for upscaling. With the method of the invention it was possible, starting from the nitro-N-oxide (3), to prepare via two chemical steps the target compound (I) in an overall yield of 84% in high purity (>99%).

Claims (13)

1. Method A method for preparing the process intermediate 4-amino-5-methylpyridone of the formula (I)
Figure US20220153699A1-20220519-C00021
comprising reacting chloro-methyl-aminopyridine (2)
Figure US20220153699A1-20220519-C00022
with KOH in methanol in an autoclave.
2. The method according to claim 1, wherein the reaction is carried out at a temperature within a range from 160° C. to 200° C.
3. The method according to claim 1, wherein the reaction is carried out at a temperature of 180° C.
4. A method for preparing the process intermediate chloro-methyl-aminopyridine (2)
Figure US20220153699A1-20220519-C00023
comprising hydrogenating a nitro-N-oxide of the formula (3)
Figure US20220153699A1-20220519-C00024
on a platinum catalyst.
5. The method according to claim 4, wherein 0.8% platinum and 0.6% molybdenum on carbon powder is used as the platinum catalyst.
6. The method according to claim 4, wherein 1% platinum and 2% vanadium on carbon powder is used as the platinum catalyst.
7. The method according to claim 4, wherein 0.5% platinum and 0.3% molybdenum on carbon powder is used as the platinum catalyst.
8. A method for preparing the process intermediate 4-amino-5-methylpyridone of the formula (I)
Figure US20220153699A1-20220519-C00025
comprising the following steps a) and b):
a) hydrogenating a nitro-N-oxide of the formula (3)
Figure US20220153699A1-20220519-C00026
 on a platinum catalyst, affording chloro-methyl-aminopyridine of the formula (2)
Figure US20220153699A1-20220519-C00027
and
b) reacting the resulting intermediate chloro-methyl-aminopyridine of the formula (2) with KOH in methanol in an autoclave.
9. The method according to claim 8, wherein 0.8% platinum and 0.6% molybdenum on carbon powder is used as the platinum catalyst in step a).
10. The method according to claim 8, wherein 1% platinum and 2% vanadium on carbon powder is used as the platinum catalyst in step a).
11. The method according to claim 8, wherein 0.5% platinum and 0.3% molybdenum on carbon powder is used as the platinum catalyst in step a).
12. The method according to claim 8, wherein in step b) the reaction is carried out at a temperature within a range from 160° C. to 200° C.
13. The method according to claim 8, wherein in step b) the reaction is carried out at a temperature of 180° C.
US17/435,606 2019-03-05 2020-02-28 Synthesis of 4-amino-5-methyl-1h-pyridin-2(1h)-on (intermediate compound for the synthesis of the mr antagonist finerenone) from 2-chloro-5-methyl-4-nitro-pyridine-1-oxide using the intermediate compound 2-chloro-5-methyl-4-pyridinamine Pending US20220153699A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19160904 2019-03-05
EP19160904.9 2019-03-05
PCT/EP2020/055292 WO2020178175A1 (en) 2019-03-05 2020-02-28 Synthesis of 4-amino-5-methyl-1h-pyridin-2(1h)-on (intermediate compound for the synthesis of the mr antagonist finerenone) from 2-chloro-5-methyl-4-nitro-pyridine-1-oxide using the intermediate compound 2-chloro-5-methyl-4-pyridinamine

Publications (1)

Publication Number Publication Date
US20220153699A1 true US20220153699A1 (en) 2022-05-19

Family

ID=65991501

Family Applications (1)

Application Number Title Priority Date Filing Date
US17/435,606 Pending US20220153699A1 (en) 2019-03-05 2020-02-28 Synthesis of 4-amino-5-methyl-1h-pyridin-2(1h)-on (intermediate compound for the synthesis of the mr antagonist finerenone) from 2-chloro-5-methyl-4-nitro-pyridine-1-oxide using the intermediate compound 2-chloro-5-methyl-4-pyridinamine

Country Status (16)

Country Link
US (1) US20220153699A1 (en)
EP (1) EP3935045A1 (en)
JP (1) JP2022523986A (en)
KR (1) KR20210135238A (en)
CN (1) CN113474332A (en)
AU (1) AU2020230965A1 (en)
BR (1) BR112021014815A2 (en)
CA (1) CA3132399A1 (en)
CL (1) CL2021002316A1 (en)
CO (1) CO2021011553A2 (en)
IL (1) IL285937A (en)
JO (1) JOP20210242A1 (en)
MX (1) MX2021010612A (en)
PE (1) PE20212199A1 (en)
SG (1) SG11202109546RA (en)
WO (1) WO2020178175A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114656400A (en) * 2022-04-26 2022-06-24 浙江科聚生物医药有限公司 Preparation method of key intermediate of non-neferitone

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1311185A (en) * 2000-03-03 2001-09-05 山东新华制药股份有限公司 Method for preparing 4-amino pyridine and its derivatives
EP1730134A1 (en) 2004-03-26 2006-12-13 Vertex Pharmaceuticals Incorporated Pyridine inhibitors of erk2 and uses thereof
DE102007009494A1 (en) 2007-02-27 2008-08-28 Bayer Healthcare Ag New 1,6-naphthyridine or 8-azaquinazoline derivatives useful for treating aldosteronism, hypertension, cardiac insufficiency, myocardial infarct sequelae, liver cirrhosis, renal insufficiency and stroke
CN103193704B (en) * 2013-04-12 2016-03-09 四川铂瑞生物医药有限公司 2-hydroxyl-4-amino-5-picoline heterogeneous ring compound
CN116655630A (en) 2014-08-01 2023-08-29 拜耳医药股份有限公司 Method for preparing compound and purification thereof for use as active pharmaceutical ingredient

Also Published As

Publication number Publication date
CA3132399A1 (en) 2020-09-10
AU2020230965A1 (en) 2021-09-23
JP2022523986A (en) 2022-04-27
CO2021011553A2 (en) 2021-09-20
CL2021002316A1 (en) 2022-04-08
IL285937A (en) 2021-10-31
CN113474332A (en) 2021-10-01
BR112021014815A2 (en) 2021-09-28
PE20212199A1 (en) 2021-11-16
WO2020178175A1 (en) 2020-09-10
SG11202109546RA (en) 2021-09-29
MX2021010612A (en) 2021-09-28
EP3935045A1 (en) 2022-01-12
JOP20210242A1 (en) 2023-01-30
KR20210135238A (en) 2021-11-12

Similar Documents

Publication Publication Date Title
JP5937087B2 (en) Process for producing dihydropteridinone and intermediates thereof
WO2013049605A1 (en) Processes for the preparation of an intermediate in the synthesis of eltrombopag
US20220153699A1 (en) Synthesis of 4-amino-5-methyl-1h-pyridin-2(1h)-on (intermediate compound for the synthesis of the mr antagonist finerenone) from 2-chloro-5-methyl-4-nitro-pyridine-1-oxide using the intermediate compound 2-chloro-5-methyl-4-pyridinamine
US5616799A (en) Process for the preparation of glycoloylanilides
JPH0556334B2 (en)
WO2016189542A1 (en) Novel process for the preparation of sapropterin dihydrochloride and its key intermediate, l-biopterin
EP0621262B1 (en) Process for the preparation of esters of 3-chloroanthranilic acid of high purity from 3-chloroanthranilic acid
CA2256251C (en) A method of producing aminocyanoacetamide
CA3132402A1 (en) Process for preparing 4-amino-5-methylpyridone
US6340773B1 (en) Preparation of halogenated primary amines
EP0052959B1 (en) Production of purine derivatives and intermediates therefor
KR920001564B1 (en) Tetrahydro isoquinoline derivatives
US4980489A (en) 2-(1-alkylaminoalkyl)-3-hydroxy-1,4-naphthoquinone
CN110551055B (en) Preparation method of 3- (4-chlorobutyl) -5-cyanoindole
JP2639709B2 (en) Novel method for producing 4&#39;-demethyl epipodophyllotoxin derivative
US6384244B2 (en) Process for preparing cis- aminochromanols
JPH072809A (en) New process for producing aminothiazoleacetic acid derivative
US6194600B1 (en) Method of producing aminocyanoacetamide
US7683189B2 (en) Process for producing aminobenzopyran compound
CN115677598A (en) Preparation method for synthesizing pyrimidinedione compound
JPH04243867A (en) Production of 2-chloro-4-pyridinemethanol
EP2332923A1 (en) 5-ý2-(methylthio)ethoxy¨pyrimidine-2-amine manufacturing method
JP2020525443A (en) Method for preparing substituted 4-aminoindan derivative
JP2000007659A (en) Production of halogeno-2(1h)-pyridone
HU199422B (en) Process for producing 8-hydroxyquinoline

Legal Events

Date Code Title Description
AS Assignment

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PLATZEK, JOHANNES;LOVIS, KAI;SIGNING DATES FROM 20210629 TO 20210701;REEL/FRAME:057539/0763

Owner name: BAYER AKTIENGESELLSCHAFT, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PLATZEK, JOHANNES;LOVIS, KAI;SIGNING DATES FROM 20210629 TO 20210701;REEL/FRAME:057539/0763

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION